NIDDK Scientists Analyze HuCAL®-Based Mini-Antibodies as a Potential Basis for Future HIV-1 Therapeutics
24 November 2005
Antibodies by Design, a division of MorphoSys AG, today announced the publication of a scientific research paper from a customer using antibodies generated from the MorphoSys HuCAL GOLD® antibody library. Using its rapid, high-throughput antibody generation system, Antibodies by Design selected a set of eight monoclonal and fully human mini-antibodies targeted specifically against the HIV-1 protein gp41 antigens provided by Dr. G. Marius Clore.
Scientists working in the team of Drs. Clore and Bewley at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – part of the U.S. National Institute of Health (NIH) – subsequently analyzed these antibodies in detail and published the results in the current edition of the Journal of Molecular Biology. The analysis demonstrates that the HuCAL®-based antibody fragments provide a set of useful probes for studying HIV-1 envelope-mediated cell fusion and may act as fusion inhibitors preventing HIV-1 virus particles from entering their target cells.
